26 April, 2024

Genekor’s participation in the 2-day Scientific Meeting on Cardiac Amyloidosis and Genetic Cardiovascular Diseases

Genekor Medical S.A. actively participated in the 2-day Scientific Meeting on Cardiac Amyloidosis and Genetic Cardiopathies on April 19 and 20 at the Cotsen Auditorium of the American School of Classical Studies in Athens. The conference, which was a continuation of last year’s meeting, was held under the auspices of the Hellenic Society of Paraclinical Diagnostic Testing, the A’ Cardiology Clinic of the University of Athens and the Unit of Cardiogenetics and Sports Cardiology (EKKAN).

This year’s conference broadened its focus beyond amyloidosis and hypertrophic cardiomyopathy, touching on the topic of rare diseases. Several physicians and scientists with expertise in these fields participated, focusing on research and clinical issues.

Genekor’s dynamic presence:

Genekor Medical S.A. was recognized for its active participation throughout the conference.

Dr. Dimitra Bouzarelou: Dr. Dimitra Bouzarelou, MSc, PhD Geneticist – Head of the Hereditary Diseases Department of Genekor Medical S.A., delivered a satellite lecture on “Beyond rare variants in cardiomyopathies: Epigenetics and Polygenic Diseases”.

Nikos Tsoulos: Nikos Tsoulos, MSc, MBA, PhDc, CEO of GeneKor Medical S.A., was invited to participate in the “Varied Lodge”, a panel with guest experts on Rare Diseases, Genetic Testing and Access to Treatments. The moderators were Professor of Cardiology and Head of the Cardiogenetics and Sports Cardiology Unit (EKKAN), H. Vlahopoulos and Professor of Cardiology, National and Kapodistrian University of Athens and Director of the 1st University Cardiology Clinic, National and Kapodistrian University of Athens, Hippocrates General Hospital, K. Tsioufis.

Nikos Tsoulos highlighted the wide application of genetic testing in Cardiology, which touches not only the diagnostic aspect but also the prognosis, the management of patients and families, as well as the differential diagnosis of phenoantibodies, such as Fabry disease and POMPE. At the same time, he stressed the rapid reduction in the cost of genetic testing.